Results 231 to 240 of about 555,062 (342)

Translocation t(1;19)(q21;q13) in acute lymphoblastic leukemia [PDF]

open access: bronze, 1984
Christiane Werner‐Favre   +3 more
openalex   +1 more source

Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ/CD19 depletion or post‐transplant cyclophosphamide

open access: yesBritish Journal of Haematology, EarlyView.
Summary Human leukocyte antigen (HLA)‐haploidentical haematopoietic cell transplantation (haplo‐HCT) is a suitable salvage strategy in children with haematological malignancies experiencing either relapse or graft failure (GF) after the first HCT.
Riccardo Masetti   +20 more
wiley   +1 more source

Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome-positive acute lymphoblastic leukemia.

open access: green, 1989
Christopher T. Denny   +7 more
openalex   +1 more source

Low rates of endothelial cell dysfunction and transplant‐related mortality in 537 children receiving fludarabine–treosulfan conditioning for all transplant indications: A retrospective multicentre study on behalf of the UK Paediatric BMT group

open access: yes
British Journal of Haematology, EarlyView.
Thomas Altmann   +11 more
wiley   +1 more source

Nonrandom abnormalities of chromosome 9p in childhood acute lymphoblastic leukemia: association with high-risk clinical features [PDF]

open access: bronze, 1989
SB Murphy   +7 more
openalex   +1 more source

CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia

open access: yesBritish Journal of Haematology, EarlyView.
Summary Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with ...
Alexandra Dreyzin   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy